within Pharmacolibrary.Drugs.ATC.J;

model J01XX12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00019833333333333335,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0342,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.048100000000000004,
    k12             = 18.6,
    k21             = 18.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lefamulin is a pleuromutilin class antibiotic indicated for the treatment of community-acquired bacterial pneumonia (CABP) in adults. It is approved and used clinically and possesses activity against a range of Gram-positive and atypical bacterial pathogens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Wicha, WW, et al., &amp; Gelone, SP (2019). Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. <i>The Journal of antimicrobial chemotherapy</i> 74(Suppl 3) iii19–iii26. DOI:<a href=\"https://doi.org/10.1093/jac/dkz087\">10.1093/jac/dkz087</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30949704/\">https://pubmed.ncbi.nlm.nih.gov/30949704</a></p></li><li><p>Wicha, WW, et al., &amp; Gelone, SP (2021). Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function. <i>Pharmacotherapy</i> 41(5) 457–462. DOI:<a href=\"https://doi.org/10.1002/phar.2522\">10.1002/phar.2522</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33811377/\">https://pubmed.ncbi.nlm.nih.gov/33811377</a></p></li><li><p>Sawicki, GS, et al., &amp; Guico-Pabia, CJ (2024). Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis. <i>Clinical therapeutics</i> 46(2) 96–103. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2023.12.002\">10.1016/j.clinthera.2023.12.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38195348/\">https://pubmed.ncbi.nlm.nih.gov/38195348</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XX12;
